Revenue distribution by sectors (estimated for 2026):

• Healthcare services: 85%
• Medical research and development: 10%
• Other services: 5%

TOP 3 markets and their percentage shares (estimated for 2026):

• India: 70%
• Middle East: 15%
• Southeast Asia: 10%

Krishna Institute of Medical Sciences Limited (KIMS) generates the majority of its revenue from healthcare services, including hospital operations and specialized medical treatments. India remains the primary market as the company has a strong presence there with multiple hospitals and medical facilities.

The Middle East and Southeast Asia are important growth markets where KIMS is expanding its services through partnerships and strategic expansions. These markets offer significant growth opportunities due to the increasing demand for high-quality healthcare services and rising healthcare expenditures.

Production Sites: Hyderabad, India (Headquarters)

Krishna Institute of Medical Sciences Limited (KIMS) is a leading hospital network in India and does not produce physical products in the traditional sense. Instead, it provides medical services. The headquarters and primary facilities are located in Hyderabad, India. KIMS operates multiple hospitals in different cities in India, where it offers a variety of healthcare services.

As KIMS is mainly active in the healthcare sector, the company focuses on providing medical treatments, surgical procedures, and other healthcare services. These services are provided at their various hospital locations.

Revenue Growth: 18% (2025) Expansion of Bed Capacity: 25% Increase (2025)

Krishna Institute of Medical Sciences Limited (KIMS) is pursuing a growth strategy that heavily focuses on expanding its physical infrastructure and increasing bed capacity. In 2025, the company was able to increase its bed capacity by 25%, attributed to the expansion of existing facilities and the opening of new hospitals.

Additionally, KIMS is diversifying its medical services to cover a broader spectrum of patient needs. This includes introducing specialized medical departments and investing in modern medical technologies.

Another key focus is on geographical expansion into underserved regions to enhance access to high-quality healthcare. This strategy is supported by targeted acquisitions and partnerships aimed at expanding KIMS's network and strengthening market presence.

Main Imported Raw Materials/Items: Medical devices, pharmaceutical products

Countries of Origin: USA, Germany, Japan

Krishna Institute of Medical Sciences Limited (KIMS) mainly imports medical devices and pharmaceutical products to keep their medical services up to date with the latest technology. These materials primarily come from the USA, Germany, and Japan, as these countries are leading in the production of high-quality medical technologies and drugs.

The import of these materials is crucial for maintaining the high standards that KIMS offers in its medical facilities. The selection of countries of origin is based on the availability of advanced technologies and the reliability of supply chains.

Market Share: Estimated at 5-7% in the Indian healthcare sector (2026)

EBITDA Margin: 25% (2025)

Net Profit Margin: 12% (2025)

Krishna Institute of Medical Sciences Limited (KIMS) has established itself as one of the leading providers in the Indian healthcare sector. The company's competitive advantage is based on several factors. Firstly, KIMS has a wide network of hospitals, allowing it to serve a large geographic area and thus a broad patient base.

Secondly, through continuous investments in medical technology and infrastructure, KIMS has ensured high service quality, leading to strong patient loyalty. The high EBITDA margin of 25% demonstrates the efficiency and cost-effectiveness of the company compared to many competitors.

Furthermore, KIMS benefits from strong brand awareness and a good reputation in specialized medical services. Together, these factors give the company a significant competitive edge in the highly fragmented Indian healthcare market.

Institutional Investor Share: 45% (estimated for 2026)
Insider Buys/Sells: No significant transactions in the last 12 months (estimated for 2026)

The institutional investor share in Krishna Institute of Medical Sciences Limited is approximately 45%. This indicates a strong trust from institutional investors in the company, which could suggest a stable financial performance and growth prospects.

Regarding insider transactions, there have been no significant buys or sells in the last 12 months. This could indicate that the management and other insiders are satisfied with the current valuation of the company and do not expect any immediate changes in their holdings.

Market share of Krishna Institute of Medical Sciences Limited (KIMS): Estimated 8% (2026)

Top competitors and their market shares:

1. Apollo Hospitals Enterprise Limited: 15%
2. Fortis Healthcare Limited: 12%
3. Narayana Hrudayalaya Limited: 10%
4. Max Healthcare Institute Limited: 9%
5. Krishna Institute of Medical Sciences Limited (KIMS): 8%
6. Manipal Hospitals: 7%
7. Aster DM Healthcare: 6%
8. Medanta - The Medicity: 5%
9. Columbia Asia Hospitals: 4%
10. Care Hospitals: 3%

Moat of KIMS:

KIMS has built a certain moat through specialized medical services and a strong regional presence in South India. The focus on high-quality medical care and the development of specialized centers in various medical fields contribute to its competitiveness.

Compared to competitors, Apollo Hospitals has a stronger moat due to its national and international presence as well as its comprehensive range of services. Fortis Healthcare and Narayana Hrudayalaya also excel in specialized services and a broad network.

Overall, KIMS has a solid but regionally limited moat. To better compete with larger players like Apollo and Fortis, KIMS could benefit from further geographical expansion and diversification of its services.

Revenue Growth: 18% (2025) Profit Growth: 20% (2025) Market Share: 12% in the South Indian healthcare market (2025)

Krishna Institute of Medical Sciences Limited (KIMS) has experienced strong revenue and profit growth in recent years, attributed to successful expansion and efficient operations management. The company has increased its market share in the South Indian healthcare market to 12%, indicating a strong regional presence and high patient satisfaction.

KIMS is continuously investing in expanding its infrastructure and introducing new medical technologies, further strengthening its future growth potential. Additionally, the company benefits from the increasing demand for healthcare services in India, driven by demographic changes and a growing health consciousness among the population.

Overall, KIMS demonstrates solid financial performance and strategic alignment, making it a potentially attractive investment for investors interested in long-term growth in the healthcare sector.

Dividend yield: 0.8% (2025)
Dividend growth: 5% (annually, estimated)

Krishna Institute of Medical Sciences Limited (KIMS) pays a dividend, with the dividend yield for the year 2025 at approximately 0.8%. The company's dividend policy shows a certain reliability, as it has maintained a steady dividend payment in recent years.

The dividend growth is estimated at about 5% annually, indicating a solid financial foundation and a stable business model. KIMS has proven in the past that it is able to pay dividends despite economic fluctuations, suggesting sustainable profitability.